Corvia Medical publishes clinical data supporting atrial shunting to reduce elevated left atrial pressure in symptomatic heart failure patients. The REDUCE LAP-HF II Trial presents five-year outcomes for heart failure with preserved and mildly reduced ejection fraction.
Gerry, with over 28 years in healthcare investment and entrepreneurship, focuses on biotechnology and medical device sectors, including infectious diseases, neurology, and cardiovascular disease. He manages Lumira Ventures’ Boston office, established in 2002.
Corvia Medical’s leadership team is comprised of professionals who share a passion and commitment to transform the standard of care for heart failure treatment. Each member of the management team brings extensive experience within the medical device field and a track record of success.
Corvia Medical is funded by Accelmed, Third Rock Ventures, General Catalyst Partners, Lumira Capital, Edwards Lifesciences, and an undisclosed strategic investor to develop the Corvia Atrial Shunt System for heart failure.
